7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Peri-Implantitis D057873 1 associated lipids
Adrenocortical Adenoma D018246 1 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Breast Neoplasms, Male D018567 1 associated lipids
Severe Combined Immunodeficiency D016511 1 associated lipids
Fluorosis, Dental D009050 1 associated lipids
Hashimoto Disease D050031 1 associated lipids
POEMS Syndrome D016878 1 associated lipids
Fibroma, Ossifying D018214 1 associated lipids
Osteolysis, Essential D010015 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Ha H et al. Lipid rafts are important for the association of RANK and TRAF6. 2003 Exp. Mol. Med. pmid:14508068
Brändström H et al. Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women. 2004 Calcif. Tissue Int. pmid:14508625
Seidlova-Wuttke D et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. 2003 Eur. J. Endocrinol. pmid:14514351
Sattler AM et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. 2004 Calcif. Tissue Int. pmid:14523602
Bergh JJ et al. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. 2004 Endocrinology pmid:14525906
Malyszko J et al. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. 2003 Transplant. Proc. pmid:14529897
Ren W et al. Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. 2003 Biomaterials pmid:14530078
Wiethe C et al. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. 2003 J. Immunol. pmid:14530334
Wagner EF and Matsuo K Signalling in osteoclasts and the role of Fos/AP1 proteins. 2003 Ann. Rheum. Dis. pmid:14532157
Ueland T et al. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. 2003 Bone pmid:14555269
Nagata N et al. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. 2003 Bone pmid:14555278
Smith BB et al. A toxicity profile of osteoprotegerin in the cynomolgus monkey. 2003 Sep-Oct Int. J. Toxicol. pmid:14555415
Cho TJ et al. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. 2003 Arthritis Rheum. pmid:14558090
von Tirpitz C et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. 2003 Eur J Gastroenterol Hepatol pmid:14560148
Fan X et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. 2004 Endocrinology pmid:14563699
Barillé-Nion S and Bataille R New insights in myeloma-induced osteolysis. 2003 Leuk. Lymphoma pmid:14565645
Novack DV TSH, the bone suppressing hormone. 2003 Cell pmid:14567908
Abe E et al. TSH is a negative regulator of skeletal remodeling. 2003 Cell pmid:14567913
Zhao ZM et al. [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. 2003 Zhonghua Xue Ye Xue Za Zhi pmid:14575594
Boyan BD et al. Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. 2003 Eur Cell Mater pmid:14577052
Grimaud E et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. 2003 Am. J. Pathol. pmid:14578201
Price PA et al. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. 2004 J. Biol. Chem. pmid:14578360
Coen G et al. Serum leptin in dialysis renal osteodystrophy. 2003 Am. J. Kidney Dis. pmid:14582047
Chagraoui H et al. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. 2003 Exp. Hematol. pmid:14585373
Takayanagi H [Crosstalk between the immune and skeletal system]. 2003 Ryumachi pmid:14598653
Naylor KE et al. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. 2003 J. Clin. Endocrinol. Metab. pmid:14602774
Heim M et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. 2004 Endocrinology pmid:14605006
Crotti TN et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. 2004 Biomaterials pmid:14607494
Hayashi S et al. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. 2003 J. Immunol. pmid:14607912
Padigel UM et al. TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. 2003 J. Immunol. pmid:14607948
Hortobagyi GN Novel approaches to the management of bone metastases. 2003 Semin. Oncol. pmid:14613037
Voskaridou E et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. 2003 Br. J. Haematol. pmid:14616979
Uemura H et al. Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. 2003 Bone pmid:14623063
Terpos E et al. New insights into the pathophysiology and management of bone disease in multiple myeloma. 2003 Br. J. Haematol. pmid:14632767
Zhang J et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. 2003 Cancer Res. pmid:14633717
Chan BY et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. 2003 Clin. Chem. pmid:14633883
Jung K et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. 2003 J. Urol. pmid:14634401
Su X et al. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. 2003 Zhonghua Nei Ke Za Zhi pmid:14636471
Mandelin J et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 J Bone Joint Surg Br pmid:14653607
Pennisi P et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. 2004 Osteoporos Int pmid:14661073
Miyahira Y et al. Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. 2003 J. Immunol. pmid:14662831
Stilgren LS et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 Calcif. Tissue Int. pmid:14667132
Okada T et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 Clin. Exp. Metastasis pmid:14669795
Gannagé-Yared MH et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. 2003 J. Endocrinol. Invest. pmid:14669830
Ashcroft AJ et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. 2003 Immunity pmid:14670302
Chong B et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. 2003 J. Bone Miner. Res. pmid:14672344
Nielsen KL et al. Biglycan deficiency interferes with ovariectomy-induced bone loss. 2003 J. Bone Miner. Res. pmid:14672350
Kumamoto H and Ooya K Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. 2004 J. Oral Pathol. Med. pmid:14675140
Crotti TN et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. 2003 J. Rheumatol. pmid:14677171
Buzi F et al. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. 2004 Clin. Endocrinol. (Oxf) pmid:14678293
Cheng X et al. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. 2004 J. Biol. Chem. pmid:14679212
Liu JZ et al. [Expression of human osteoprotegerin gene in E. Coli and bioactivity analysis of expression product]. 2003 Zhonghua Wai Ke Za Zhi pmid:14680558
Yamada Y et al. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. 2003 Mol. Genet. Metab. pmid:14680982
Ogasawara T et al. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. 2004 J. Periodont. Res. pmid:14687227
Brubaker KD et al. Bone morphogenetic protein signaling in prostate cancer cell lines. 2004 J. Cell. Biochem. pmid:14689587
Gehrke T et al. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. 2003 Scand. J. Rheumatol. pmid:14690142
Zhang D et al. The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. 2004 Arch. Oral Biol. pmid:14693199
Stolina M et al. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. 2003 Clin. Immunol. pmid:14697750
Blair HC and Athanasou NA Recent advances in osteoclast biology and pathological bone resorption. 2004 Histol. Histopathol. pmid:14702187
Vegni FE et al. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. 2004 N. Engl. J. Med. pmid:14711922
Crisafulli A et al. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. 2004 J. Clin. Endocrinol. Metab. pmid:14715848
Onyia JE et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. 2004 J. Pharmacol. Exp. Ther. pmid:14718597
Skoumal M et al. Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. 2004 Ann. Rheum. Dis. pmid:14722219
Hofbauer LC et al. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. 2004 Clin. Endocrinol. (Oxf) pmid:14725683
Yoneda T et al. Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. 2004 Endocrinology pmid:14726437
Wittrant Y et al. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. 2004 Exp. Cell Res. pmid:14729467
Hruska KA et al. Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. 2004 Semin. Nephrol. pmid:14730507
Zwerina J et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. 2004 Arthritis Rheum. pmid:14730626
Mallat Z and Tedgui A Unbalanced RANKL/RANK pathway in aortic valve sclerosis. 2004 J. Mol. Cell. Cardiol. pmid:14734042
Kaden JJ et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. 2004 J. Mol. Cell. Cardiol. pmid:14734048
Guillonneau C et al. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. 2004 J. Immunol. pmid:14734743
Sudhoff H et al. [Expression of osteoclast stimulating and differentiating factors in a murine model of localized inflammatory bone resorption]. 2004 Laryngorhinootologie pmid:14740300
Findlay DM et al. The proliferation and phenotypic expression of human osteoblasts on tantalum metal. 2004 Biomaterials pmid:14741587
Theoleyre S et al. Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. 2004 Biochim. Biophys. Acta pmid:14741739
Redlich K et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. 2004 Am. J. Pathol. pmid:14742260
Mogi M et al. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. 2004 J. Dent. Res. pmid:14742657
Takayanagi H [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. 2003 Seikagaku pmid:14748148
Itonaga I et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. 2004 Bone pmid:14751563
Pan B et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). 2004 J. Bone Miner. Res. pmid:14753746
Valverde P et al. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. 2004 J. Bone Miner. Res. pmid:14753747
Amizuka N et al. Defective bone remodelling in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756238
Kawana F and Sasaki T Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756239
Suda K et al. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. 2004 J. Immunol. pmid:14764723
Saidenberg-Kermanac'h N et al. Role for osteoprotegerin in rheumatoid inflammation. 2004 Joint Bone Spine pmid:14769514
Durán A et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. 2004 Dev. Cell pmid:14960283
Wang FS et al. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. 2004 Endocrinology pmid:14962990
Harashima SI et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. 2004 Rheumatology (Oxford) pmid:14963213
Huang JC et al. PTH differentially regulates expression of RANKL and OPG. 2004 J. Bone Miner. Res. pmid:14969393
He J et al. Emdogain promotes osteoblast proliferation and differentiation and stimulates osteoprotegerin expression. 2004 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:14970783
Ohazama A et al. Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis. 2004 J. Dent. Res. pmid:14981127
Gruber HE and Rude RK Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. 2003 Biotech Histochem pmid:14989640
Kubota A et al. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. 2004 J. Rheumatol. pmid:14994384
Kötter I and Stübiger N Therapeutic implications for interferon-alpha in arthritis. 2004 J. Rheumatol. pmid:14994421
Schett G et al. Soluble RANKL and risk of nontraumatic fracture. 2004 JAMA pmid:14996780
Tsuji K et al. Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. 2004 J. Bone Miner. Metab. pmid:14999519
Jørgensen HL et al. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. 2004 J. Bone Miner. Metab. pmid:14999524
Wagner TU et al. The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. 2003 Adv Space Res pmid:15000082
Baek KH et al. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. 2004 J. Clin. Endocrinol. Metab. pmid:15001618
Brage M et al. Osteoclastogenesis is decreased by cysteine proteinase inhibitors. 2004 Bone pmid:15003789
Fukunaga J et al. Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. 2004 Bone pmid:15003790

Table of Content